| Literature DB >> 32414163 |
Dongbo Xu1, Erli Tian1, Fandong Kong2, Kui Hong1.
Abstract
Five new compounds 15R-17,18-dehydroxantholipin (1), (3E,5E,7E)-3-methyldeca-3,5,7-triene-2,9-dione (2) and qinlactone A-C (3-5) were identified from mangrove Streptomyces qinglanensis 172205 with "genetic dereplication," which deleted the highly expressed secondary metabolite-enterocin biosynthetic gene cluster. The chemical structures were established by spectroscopic methods, and the absolute configurations were determined by electronic circular dichroism (ECD). Compound 1 exhibited strong anti-microbial and antiproliferative bioactivities, while compounds 2-4 showed weak antiproliferative activities.Entities:
Keywords: anti-microbial; antiproliferative; genetic dereplication; mangrove Streptomyces
Mesh:
Substances:
Year: 2020 PMID: 32414163 PMCID: PMC7281499 DOI: 10.3390/md18050255
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1(a) The organization of enterocin biosynthetic gene cluster before and after deletion. Amplification fragments by verifying primers were labeled by fronts in red; (b) HPLC detection of crude extracts of strain 172205 wild type and Δenc in D.O. medium.
Figure 2Chemical structures of compound 1–5.
1H and 13C NMR data for Compound 1–2.
| Position | 1 | 2 | ||||
|---|---|---|---|---|---|---|
| HMBC | HMBC | |||||
| 1 | 133.6, C | 2.38 s | 26.0, CH3 | C-2, 4 | ||
| 2 | 7.63 d (8.8) | 125.9, CH | C-1, 4, 6 | 202.0, C | ||
| 3 | 7.95 d (8.4) | 120.8, CH | C-1, 5, 10 | 140.7, C | ||
| 4 | 120.6, C | 7.28 d (11.4) | 139.6, CH | C-2, 6, 11 | ||
| 5 | 149.7, C | 7.16 dd (11.5, 14.6) | 137.9, CH | C-3, 7 | ||
| 6 | 144.6, C | 6.84 dd (11.2, 14.6) | 138.8, CH | C-4, 7, 8 | ||
| 7 | 7.41 dd (11.1, 15.6) | 144.5, CH | C-5, 6, 9 | |||
| 8 | 143.4, C | 6.31 d (15.7) | 133.7, CH | C-6, 9, 10 | ||
| 9 | 108.2 *, C | 201.3, C | ||||
| 10 | 181.4, C | 2.32 s | 27.4, CH3 | C-7, 8, 9 | ||
| 11 | 158.9, C | 1.94 d (1.0) | 12.0, CH3 | C-2, 3 | ||
| 12 | 109.5 *, C | |||||
| 13 | 131.4, C | |||||
| 14 | 131.3, C | |||||
| 15 | 5.15 dd (6.4, 14.0) | 71.1, CH | ||||
| 16 | a, 2.37 m | 25.3, CH2 | C-13, 15, 17, 18 | |||
| b, 2.54 overlapped | ||||||
| 17 | 136.0 **, C | |||||
| 18 | 141.5 **, C | |||||
| 19 | 178.6, C | |||||
| 20 | 117.3, C | |||||
| 21 | 145.1, C | |||||
| 22 | 182.8, C | |||||
| 23 | 6.55 s | 99.6, CH | C-20, 22, 24, 27 | |||
| 24 | 154.5, C | |||||
| 25-NH | 12.67 s | C-20, 23, 26, 27 | ||||
| 26 | 151.9, C | |||||
| 27 | 2.36 s | 19.5, CH3 | C-23, 24 | |||
| 28 | a, 5.71 d (5.9) | 91.3, CH2 | C-14, 15 | |||
| 29 | 4.08 s | 61.6, CH3 | C-6 | |||
| 11-OH | 12.67 s | C-9 | ||||
*, ** Assignments are made in comparison with literature data for similar reported compounds. 1 (800 and 200 MHz, DMSO-d, δ in ppm); 2 (500 and 125 MHz, CD3OD-d, δ in ppm).
Figure 3Key heteronuclear multiple bond coherence (HMBC), homonuclear correlation spectroscopy (COSY) and rotating frame overhauser effect spectroscopy (ROESY) correlations of compound 1–5.
Figure 4Experimental and calculated electronic circular dichroism (ECD) spectra for compound 1, 3 and 4.
1H and 13C NMR data for Compound 3–5 (500 and 125 MHz, CD3OD-d, δ in ppm).
| Position | 3 | 4 | 5 | ||||||
|---|---|---|---|---|---|---|---|---|---|
| HMBC | HMBC | HMBC | |||||||
| 1 | 183.3, C | 182.6, C | 183.4, C | ||||||
| 2 | 45.9, C | 44.9, C | 45.0, C | ||||||
| 3 | 3.96 s | 81.5, CH | C-1, 2, 4, 5, 13, 14 | 3.98 s | 83.8, CH | C- 2, 4, 5, 13, 14 | 4.53 s | 75.1, CH | C-2, 4, 5, 14, 15 |
| 4 | 88.0, C | 86.2, C | 90.4, C | ||||||
| 5 | 6.14 d (15.4) | 142.1, CH | C- 3, 4, 7, 15 | 6.27 d (15.6) | 139.0, CH | C- 4, 6, 7, 15 | 3.63 d (2.3) | 77.9, CH | C-3, 4, 7, 15 |
| 6 | 6.46 dd (9.9, 15.4) | 129.8, CH | C-4, 7, 8 | 6.46 dd (9.8,15.6) | 130.2, CH | C-4, 5, 8 | 4.44 d (5.8) | 72.8, CH | C-7, 8 |
| 7 | 6.71 overlapped | 140.7, CH | C-6 | 6.71 overlapped | 141.0, CH | C-8, 9 | 6.35 dd (5.6, 15.3) | 144.4, CH | C-6, 9 |
| 8 | 6.71 overlapped | 130.6, CH | C-6, 7 | 6.71 overlapped | 130.4, CH | 6.78 dd (11.2, 15.1) | 127.9, CH | C-6, 9, 10 | |
| 9 | 7.23 dd (1.0, 10.3) | 141.3, CH | C-6, 8, 11, 16 | 7.23 dd (1.0, 10.0) | 141.5, CH | C-7, 8, 11, 16 | 7.22 d (11.1) | 141.1, CH | C-7, 8, 11, 16 |
| 10 | 137.7, C | 137.5, C | 137.3, C | ||||||
| 11 | 202.2, C | 202.3, C | 202.5, C | ||||||
| 12 | 2.34 s | 25.8, CH3 | C-9, 10, 11 | 2.33 s | 25.8, CH3 | C-9, 10, 11 | 2.34 s | 25.8, CH3 | C-9, 10, 11 |
| 13 | 1.19 s | 20.5, CH3 | C-1, 2, 3, 14 | 1.21 s | 25.3, CH3 | C-1, 2, 3, 14 | 1.24 s | 25.6, CH3 | C-1, 2, 3, 14 |
| 14 | 1.22 s | 26.3, CH3 | C-1, 2, 3, 13 | 1.04 s | 19.9, CH3 | C-1, 2, 3, 13 | 1.20 s | 21.2, CH3 | C-1, 2, 13 |
| 15 | 1.46 s | 22.1, CH3 | C-3, 4, 5, 6 | 1.52 s | 27.4, CH3 | C-3, 4, 5, 6 | 1.43 s | 19.3, CH3 | C-3, 4, 5, |
| 16 | 1.87 d (1.0) | 11.7, CH3 | C-8, 9, 10, 11 | 1.87 d (0.8) | 11.7, CH3 | C-8, 9, 10, 11 | 1.87 s | 11.6, CH3 | C-9, 10, 11 |
MIC (μg/mL) against pathogenic microbes of compounds 1–5. E. coli: Escherichia coli; S. aureus: Staphylococcus aureus; C. albicans: Candida albicans.
| Compound. |
|
|
|
|---|---|---|---|
|
| >100 | 0.78 | 3.13 |
| kanamycin | 6.25 | 6.25 | / |
| nystatin | / | / | 3.13 |
Cytotoxicities against MCF-7 and HeLa cells of compound 1–5 (µM).
| Compound | MCF-7 (IC50 ± SD, 48 h) | HeLa (IC50 ± SD, 48 h) |
|---|---|---|
|
| 5.78 ± 0.26 | 6.25 ± 0.29 |
|
| 206.91 ± 9.69 | 183.03 ± 11.11 |
|
| >179.86 | 168.13 ± 13.15 |
|
| 136.87 ± 10.67 | 129.14 ± 3.98 |
| Paclitaxel | <0.46 | <0.46 |